Follow
← Back
Medicines · Interactions

Mercaptopurine — interactions

Other medicines, foods and herbal products can change how Mercaptopurine works. Everything on this page comes from Mercaptopurine's own FDA-approved label — the same source as the main guide.

← Back to the full Mercaptopurine guide

⚠ Caution: Allopurinol : Reduce the dose of Mercaptopurine Tablets when co-administered with allopurinol. Warfarin : Mercaptopurine Tablets may decrease the anticoagulant effect.

Medicines named in Mercaptopurine's label

Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.

Section 7.1 of the label

Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) . Reduce the dose of Mercaptopurine Tablets when coadministered with allopurinol .

Section 7.2 of the label

Warfarin The concomitant administration of Mercaptopurine Tablets and warfarin may decrease the anticoagulant effectiveness of warfarin. Monitor the international normalized ratio (INR) in patients receiving warfarin and adjust the warfarin dosage as appropriate.

Myelosuppressive Products

Mercaptopurine Tablets can cause myelosuppression. Myelosuppression may be increased when Mercaptopurine Tablets are coadministered with other products that cause myelosuppression. Enhanced myelosuppression has been noted in some patients also receiving trimethoprim-sulfamethoxazole. Monitor the CBC and adjust the dose of Mercaptopurine Tablets for excessive myelosuppression .

Section 7.4 of the label

Aminosalicylates Aminosalicylates (e.g., mesalamine, olsalazine or sulfasalazine) may inhibit the TPMT enzyme, which may increase the risk of myelosuppression when coadministered with Mercaptopurine Tablets. When aminosalicylates and Mercaptopurine Tablets are coadministered, use the lowest possible doses for each drug and monitor more frequently for myelosuppression .

Hepatotoxic Products

Mercaptopurine Tablets can cause hepatotoxicity. Hepatotoxicity may be increased when Mercaptopurine Tablets are coadministered with other products that cause hepatotoxicity. Monitor liver tests more frequently in patients who are receiving Mercaptopurine Tablets with other hepatotoxic products .

Mercaptopurine's label names 4 medicines that NepalDoc also covers.

Their interaction pages

These medicines named in Mercaptopurine's label have interaction pages of their own:

Read the full interactions section from Mercaptopurine's label

Allopurinol : Reduce the dose of Mercaptopurine Tablets when co-administered with allopurinol. Warfarin : Mercaptopurine Tablets may decrease the anticoagulant effect.

7.1 Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) . Reduce the dose of Mercaptopurine Tablets when coadministered with allopurinol .

7.2 Warfarin The concomitant administration of Mercaptopurine Tablets and warfarin may decrease the anticoagulant effectiveness of warfarin. Monitor the international normalized ratio (INR) in patients receiving warfarin and adjust the warfarin dosage as appropriate.

7.3 Myelosuppressive Products Mercaptopurine Tablets can cause myelosuppression. Myelosuppression may be increased when Mercaptopurine Tablets are coadministered with other products that cause myelosuppression. Enhanced myelosuppression has been noted in some patients also receiving trimethoprim-sulfamethoxazole. Monitor the CBC and adjust the dose of Mercaptopurine Tablets for excessive myelosuppression .

7.4 Aminosalicylates Aminosalicylates (e.g., mesalamine, olsalazine or sulfasalazine) may inhibit the TPMT enzyme, which may increase the risk of myelosuppression when coadministered with Mercaptopurine Tablets. When aminosalicylates and Mercaptopurine Tablets are coadministered, use the lowest possible doses for each drug and monitor more frequently for myelosuppression .

7.5 Hepatotoxic Products Mercaptopurine Tablets can cause hepatotoxicity. Hepatotoxicity may be increased when Mercaptopurine Tablets are coadministered with other products that cause hepatotoxicity. Monitor liver tests more frequently in patients who are receiving Mercaptopurine Tablets with other hepatotoxic products .

Mercaptopurine guide · All interaction pages · Medicines A–Z

SourcesU.S. FDA-approved label via DailyMed (label effective 25 Feb 2026) · National List of Essential Medicines, Nepal (2021) · U.S. labeling may differ from Nepal DDA-approved labeling and local prescribing practice.

This page summarises Mercaptopurine's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.

Search medicines in the app / एपमा औषधि खोज्नुहोस् Find a pharmacy / फार्मेसी खोज्नुहोस्
+ Safety information

This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.

Share this Medicine
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.